Developer docs
API playgroundTry for free, no card

Search company profiles

RCE

Full company profile

uuid0002576

Namestring
RCE
Legal namestring
RCE Technologies, Inc.
Websiteurl
rce.ai
Company typeenum
Private
Founded yearint
2018
Descriptiontext

RCE Technologies, Inc. is a pre-commercial medical technology company developing the Infrasensor, a wrist-worn wearable device that uses proprietary mid-infrared (MIR) spectroscopy combined with deep learning to detect early stages of severe coronary artery occlusion non-invasively. The device captures transdermal derived infrared spectrophotometric (TDIS) waveforms through the skin, processes them via proprietary ML algorithms, and delivers a cardiac assessment in approximately three minutes without the need for an invasive blood draw. RCE is pursuing FDA de novo pre-market clearance, with a pivotal study in Emergency Departments initiated in 2025 and FDA presubmission already completed.

The company's core technology rests on four issued US patents covering infrared sensor architecture, cardiac monitoring methods, and the wearable form factor, supported by a proprietary clinical dataset of 840+ patients enrolled across 10 US hospital sites. RCE's clinical evidence has been validated through publication in Nature Communications Medicine and the European Heart Journal, and through presentations at the American College of Cardiology Late Breaking Clinical Trials. The company's Scientific Advisory Board includes KOL cardiologists from leading academic centers (Baylor College of Medicine, Rutgers Robert Wood Johnson, and others), and its leadership includes a Chief Medical Officer with prior service as Senior Medical Officer at the FDA's Digital Health Center of Excellence.

RCE's go-to-market is sales-led and clinically validated, initially targeting Emergency Departments, urgent care facilities, and EMS/ambulance services, with secondary use cases in pharmaceutical cardiovascular drug trials and at-home monitoring of high-risk CAD patients. The company has secured a first commercial Letter of Intent, but remains pre-revenue. Future expansion includes the Infrasensor-home consumer wearable and licensing its AI sensor technology for integration into existing patch and watch-based platforms. The company is headquartered in Carlsbad, California, was founded in 2018, and has completed accelerator programs at TMCx and Cedars-Sinai.

Short descriptiontext

RCE Technologies is a pre-commercial med-tech company developing the Infrasensor, a wrist-worn wearable that uses proprietary mid-infrared spectroscopy and machine learning to detect early stages of severe heart attacks non-invasively, targeting hospital emergency departments, urgent care, and EMS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac biomarker detection, infrared spectroscopy wearables, heart attack diagnostics, non-invasive cardiac monitoring, medical infrared sensors
Industry4 codes
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Diagnostic Medical Devices
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Wearable Device Sales
TypeHardware Sales
Description

Pre-commercial stage. Revenue expected from sale of wrist-worn wearable devices with integrated infrared sensors for cardiac monitoring.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Infrasensor
Description

A non-invasive wrist-worn device for detection of high-grade obstructive Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) using infrared spectroscopy technology.

rce.ai
Core offering1 text field

RCE Technologies develops and is commercializing the Infrasensor, a wrist-worn wearable medical device that combines proprietary mid-infrared spectroscopy sensors with cloud-based machine learning to non-invasively measure cardiac biomarkers transdermally and detect early stages of severe coronary artery occlusion (high-grade obstructive NSTE-ACS) in approximately three minutes. The investigational device is targeted at hospital emergency departments, urgent care centers, EMS providers, pharmaceutical trial sponsors, and high-risk at-home CAD patients, with FDA de novo pre-market clearance currently in process.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 3-minute non-invasive cardiac assessment
+1 more record
Product and service1 record
1Infrasensor
CategoryCardiac Diagnostic Medical Device
Description

A wrist-worn wearable medical device that uses proprietary mid-infrared spectroscopy sensors and cloud-based machine learning to non-invasively analyze Transdermal Derived Infrared Spectrophotometric (TDIS) waveforms from the skin and detect early stages of severe coronary artery occlusion (high-grade obstructive NSTE-ACS) in approximately three minutes. Currently an investigational device used for research only, pending FDA de novo pre-market clearance; intended for hospital emergency departments, urgent care centers, EMS providers, and pharmaceutical trial sponsors.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

American Heart Association is a key strategic partner and has recognized RCE as a Health Tech Winner. The partnership provides credibility in the cardiovascular health space and access to AHA's network and resources.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

RCE participated in the Cedars-Sinai Accelerator program, gaining access to clinical expertise, hospital network validation opportunities, and mentorship from healthcare industry veterans.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

RCE completed the TMCx accelerator program, providing access to the world's largest medical complex for clinical validation and healthcare system partnerships.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AliveCor makes KardiaMobile, a clinical-grade single-lead ECG device for at-home and point-of-care cardiac rhythm assessment. It is the closest direct peer because it sells a consumer/clinical hardware device using AI/ML to detect cardiac abnormalities (arrhythmias) outside the hospital, overlapping with RCE's wrist-worn AI cardiac biomarker platform in use case and customer profile.

TypeDirect peer
Description

iRhythm's Zio long-term ambulatory ECG patch and AI-based arrhythmia detection platform is a direct clinical cardiology diagnostic competitor. It shares RCE's profile of an AI-enabled wearable cardiac diagnostic with FDA clearance, hospital channel sales, and reimbursement-driven economics.

TypeDirect peer
Description

Eko combines digital stethoscopes with FDA-cleared AI algorithms (including for cardiac biomarkers and murmurs) for clinicians in primary care and ED settings. It competes on the same problem RCE solves, using a different sensor modality, and shares a hospital sales motion plus AI/ML device regulatory playbook.

TypeDirect peer
Description

HeartFlow provides AI-driven non-invasive cardiac diagnostics (CT-derived FFR) for coronary artery disease assessment. It is comparable as an AI-first, non-invasive alternative to invasive cardiac diagnostics sold into the same cardiology customer base as RCE.

5Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's ARCHITECT and Alinity high-sensitivity troponin assays plus its i-STAT point-of-care troponin platform dominate the ED cardiac biomarker market that RCE would enter. Comparable as the incumbent whose installed base, turnaround improvements, and hospital contracts RCE must displace or complement.

TypeBroad incumbent
Description

Roche's Elecsys high-sensitivity troponin-T assays are the global standard for ED cardiac biomarker testing. Relevant as the entrenched competitor with deep hospital integration, continuous assay improvements, and clinical guideline endorsements that RCE must compete against.

TypeBroad incumbent
Description

Siemens Healthineers markets Atellica and ADVIA Centaur high-sensitivity troponin-I assays and a broad hospital diagnostics portfolio. It is comparable as an incumbent cardiac biomarker vendor whose assay iteration cadence sets the competitive bar for RCE's launch.

TypeBroad incumbent
Description

GE HealthCare's MUSE ECG management, inpatient telemetry/monitoring, and patient monitoring portfolio competes in the same hospital cardiology workflow RCE targets. Relevant as a broad incumbent with established hospital relationships and integrated cardiology IT platforms.

TypeBroad incumbent
Description

Philips sells cardiac telemetry, ECG, and acute care monitoring solutions into hospital systems globally. Comparable as a broad incumbent selling into the same cardiology and ED/ICU buyer, with established integration, training, and service infrastructure that RCE would need to match.

TypeEmerging player
Description

Cleerly applies AI to cardiac CT imaging for plaque and stenosis assessment in coronary artery disease. It overlaps with RCE as an emerging AI-driven, non-invasive cardiology diagnostic targeting similar hospital and cardiology customers, though with an imaging rather than wearable sensor modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RCE

Cardiac Diagnostic Medical Devicesrce.ai

RCE Technologies is a pre-commercial med-tech company developing the Infrasensor, a wrist-worn wearable that uses proprietary mid-infrared spectroscopy and machine learning to detect early stages of severe heart attacks non-invasively, targeting hospital emergency departments, urgent care, and EMS.

What RCE does

RCE Technologies, Inc. is a pre-commercial medical technology company developing the Infrasensor, a wrist-worn wearable device that uses proprietary mid-infrared (MIR) spectroscopy combined with deep learning to detect early stages of severe coronary artery occlusion non-invasively. The device captures transdermal derived infrared spectrophotometric (TDIS) waveforms through the skin, processes them via proprietary ML algorithms, and delivers a cardiac assessment in approximately three minutes without the need for an invasive blood draw. RCE is pursuing FDA de novo pre-market clearance, with a pivotal study in Emergency Departments initiated in 2025 and FDA presubmission already completed.

The company's core technology rests on four issued US patents covering infrared sensor architecture, cardiac monitoring methods, and the wearable form factor, supported by a proprietary clinical dataset of 840+ patients enrolled across 10 US hospital sites. RCE's clinical evidence has been validated through publication in Nature Communications Medicine and the European Heart Journal, and through presentations at the American College of Cardiology Late Breaking Clinical Trials. The company's Scientific Advisory Board includes KOL cardiologists from leading academic centers (Baylor College of Medicine, Rutgers Robert Wood Johnson, and others), and its leadership includes a Chief Medical Officer with prior service as Senior Medical Officer at the FDA's Digital Health Center of Excellence.

RCE's go-to-market is sales-led and clinically validated, initially targeting Emergency Departments, urgent care facilities, and EMS/ambulance services, with secondary use cases in pharmaceutical cardiovascular drug trials and at-home monitoring of high-risk CAD patients. The company has secured a first commercial Letter of Intent, but remains pre-revenue. Future expansion includes the Infrasensor-home consumer wearable and licensing its AI sensor technology for integration into existing patch and watch-based platforms. The company is headquartered in Carlsbad, California, was founded in 2018, and has completed accelerator programs at TMCx and Cedars-Sinai.

RCE firmographics

Firmographics
Name
RCE
Legal name
RCE Technologies, Inc.
Website
https://rce.ai
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
RCE Technologies is a pre-commercial med-tech company developing the Infrasensor, a wrist-worn wearable that uses proprietary mid-infrared spectroscopy and machine learning to detect early stages of severe heart attacks non-invasively, targeting hospital emergency departments, urgent care, and EMS.
Ownership category
akta.pro rank

RCE industry classification

Industry
Product category
Cardiac Diagnostic Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Cardiac biomarker detection
  • Infrared spectroscopy wearables
  • Heart attack diagnostics
  • Non-invasive cardiac monitoring
  • Medical infrared sensors

Where RCE is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices1 record

Markets served

RCE business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Wearable Device Sales: Pre-commercial stage. Revenue expected from sale of wrist-worn wearable devices with integrated infrared sensors for cardiac monitoring.

Go-to-market motion3 records

Marketing channels5 records

RCE product offering

Product offering

Core offering

RCE Technologies develops and is commercializing the Infrasensor, a wrist-worn wearable medical device that combines proprietary mid-infrared spectroscopy sensors with cloud-based machine learning to non-invasively measure cardiac biomarkers transdermally and detect early stages of severe coronary artery occlusion (high-grade obstructive NSTE-ACS) in approximately three minutes. The investigational device is targeted at hospital emergency departments, urgent care centers, EMS providers, pharmaceutical trial sponsors, and high-risk at-home CAD patients, with FDA de novo pre-market clearance currently in process.

Differentiator

Problem solved

Functional benefit

Brands

  • Infrasensor: A non-invasive wrist-worn device for detection of high-grade obstructive Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) using infrared spectroscopy technology.

Products and services

  • Infrasensor A wrist-worn wearable medical device that uses proprietary mid-infrared spectroscopy sensors and cloud-based machine learning to non-invasively analyze Transdermal Derived Infrared Spectrophotometric (TDIS) waveforms from the skin and detect early stages of severe coronary artery occlusion (high-grade obstructive NSTE-ACS) in approximately three minutes. Currently an investigational device used for research only, pending FDA de novo pre-market clearance; intended for hospital emergency departments, urgent care centers, EMS providers, and pharmaceutical trial sponsors.

Quantifiable outcome

  • 3-minute non-invasive cardiac assessment
  • +1 more outcomes

Companies that use RCE

Customer profile

Segments5 records

Ideal customer profiles4 records

RCE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

RCE partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • American Heart AssociationflagshipStrategic or Co-development PartnerAmerican Heart Association is a key strategic partner and has recognized RCE as a Health Tech Winner. The partnership provides credibility in the cardiovascular health space and access to AHA's network and resources.
  • Cedars-Sinai AcceleratorcoreStrategic or Co-development PartnerRCE participated in the Cedars-Sinai Accelerator program, gaining access to clinical expertise, hospital network validation opportunities, and mentorship from healthcare industry veterans.
  • Texas Medical Center (TMCx)coreStrategic or Co-development PartnerRCE completed the TMCx accelerator program, providing access to the world's largest medical complex for clinical validation and healthcare system partnerships.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

RCE competitors and assessment

Company assessment

Direct peers

  • AliveCor: AliveCor makes KardiaMobile, a clinical-grade single-lead ECG device for at-home and point-of-care cardiac rhythm assessment. It is the closest direct peer because it sells a consumer/clinical hardware device using AI/ML to detect cardiac abnormalities (arrhythmias) outside the hospital, overlapping with RCE's wrist-worn AI cardiac biomarker platform in use case and customer profile.
  • iRhythm Technologies: iRhythm's Zio long-term ambulatory ECG patch and AI-based arrhythmia detection platform is a direct clinical cardiology diagnostic competitor. It shares RCE's profile of an AI-enabled wearable cardiac diagnostic with FDA clearance, hospital channel sales, and reimbursement-driven economics.
  • Eko Health: Eko combines digital stethoscopes with FDA-cleared AI algorithms (including for cardiac biomarkers and murmurs) for clinicians in primary care and ED settings. It competes on the same problem RCE solves, using a different sensor modality, and shares a hospital sales motion plus AI/ML device regulatory playbook.
  • HeartFlow: HeartFlow provides AI-driven non-invasive cardiac diagnostics (CT-derived FFR) for coronary artery disease assessment. It is comparable as an AI-first, non-invasive alternative to invasive cardiac diagnostics sold into the same cardiology customer base as RCE.

Broad incumbents

  • Abbott Diagnostics: Abbott's ARCHITECT and Alinity high-sensitivity troponin assays plus its i-STAT point-of-care troponin platform dominate the ED cardiac biomarker market that RCE would enter. Comparable as the incumbent whose installed base, turnaround improvements, and hospital contracts RCE must displace or complement.
  • Roche Diagnostics: Roche's Elecsys high-sensitivity troponin-T assays are the global standard for ED cardiac biomarker testing. Relevant as the entrenched competitor with deep hospital integration, continuous assay improvements, and clinical guideline endorsements that RCE must compete against.
  • Siemens Healthineers: Siemens Healthineers markets Atellica and ADVIA Centaur high-sensitivity troponin-I assays and a broad hospital diagnostics portfolio. It is comparable as an incumbent cardiac biomarker vendor whose assay iteration cadence sets the competitive bar for RCE's launch.
  • GE HealthCare: GE HealthCare's MUSE ECG management, inpatient telemetry/monitoring, and patient monitoring portfolio competes in the same hospital cardiology workflow RCE targets. Relevant as a broad incumbent with established hospital relationships and integrated cardiology IT platforms.
  • Philips (Cardiac Monitoring): Philips sells cardiac telemetry, ECG, and acute care monitoring solutions into hospital systems globally. Comparable as a broad incumbent selling into the same cardiology and ED/ICU buyer, with established integration, training, and service infrastructure that RCE would need to match.

Emerging players

  • Cleerly Health: Cleerly applies AI to cardiac CT imaging for plaque and stenosis assessment in coronary artery disease. It overlaps with RCE as an emerging AI-driven, non-invasive cardiology diagnostic targeting similar hospital and cardiology customers, though with an imaging rather than wearable sensor modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

RCE social profiles

Digital presence

RCE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RCE leadership team

Management profile

Number of profiles

Profiles9 records

RCE funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RCE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RCE

What does RCE do?

RCE Technologies develops and is commercializing the Infrasensor, a wrist-worn wearable medical device that combines proprietary mid-infrared spectroscopy sensors with cloud-based machine learning to non-invasively measure cardiac biomarkers transdermally and detect early stages of severe coronary artery occlusion (high-grade obstructive NSTE-ACS) in approximately three minutes. The investigational device is targeted at hospital emergency departments, urgent care centers, EMS providers, pharmaceutical trial sponsors, and high-risk at-home CAD patients, with FDA de novo pre-market clearance currently in process.

Is RCE a public or private company?

RCE is a private company. It is classified as venture growth investor backed and is currently operating.

When was RCE founded?

RCE was founded in 2018. It employs 51 to 100 people.

Where is RCE based?

RCE is headquartered in Carlsbad, United States, in the North America region.

How does RCE make money?

One revenue line is on record: wearable Device Sales.

Who are RCE's main competitors?

Direct peers on record are AliveCor, iRhythm Technologies, Eko Health and HeartFlow. Broad incumbents are Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, GE HealthCare and Philips (Cardiac Monitoring). Cleerly Health is listed as an emerging player.

Does RCE have an API?

No public API is recorded for RCE.

What industry is RCE in?

RCE's product category is Cardiac Diagnostic Medical Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ZDNETRemote code execution vulnerabilities uncovered in smart air fryerResearchers from Cisco Talos disclosed two remote code execution vulnerabilities in the Cosori Smart Air Fryer, including an unauthenticated backdoor and a heap-based overflow. Cosori said the flaws are limited to the local area network and a firmware update is due for release on April 25.ZDNETCritical Zoom vulnerability triggers remote code execution without user inputResearchers Daan Keuper and Thijs Alkemade discovered a zero-day Zoom vulnerability enabling remote code execution without user input, earning $200,000. The attack works on Windows and Mac Zoom, but not iOS, Android, or the browser version. Zoom is working to mitigate the issue, with a 90-day patch window.SC MediaBug allows attackers to hijack Windows time sync software used to track security incidentsGRIMM researchers found a remote code execution vulnerability in Greyware's Domain Time II time synchronization software, allowing attackers to hijack its update process via a man-on-the-side attack. A patch was released on March 31, and the vulnerability could let attackers inject malware into updates, potentially disrupting security incident tracking and financial transaction ordering.The Hacker NewsCritical RCE Flaw Reported in MyBB Forum Software—Patch Your SitesIndependent researchers discovered two critical vulnerabilities in MyBB forum software, including a nested auto URL persistent XSS and an SQL injection, enabling remote code execution. The MyBB team released version 1.8.26 on March 10 to address the issues, and at least 2,100 potentially vulnerable domains were identified.Security AffairsCisco fixes critical remote code execution issues in SMB VPN routersCisco fixed multiple pre-auth remote code execution flaws in small business VPN routers, allowing unauthenticated attackers to execute arbitrary code as root. The vulnerabilities, with a CVSS score of 9.8/10, affect RV160, RV160W, RV260, RV260P, and RV260W models running firmware earlier than 1.0.01.02. Cisco's PSIRT is not aware of attacks in the wild.ZapierSerious bug discovered in widely used cryptographic softwareA remote code execution vulnerability in Libgcrypt 1.9.0, used by GnuPG, allows arbitrary code execution via a heap buffer overflow. The developers released version 1.9.1 as a fix, and GnuPG users are urged to upgrade immediately.CaptainFreakThe Secret Parameter, LFR, and Potential RCE in NodeJS AppsA NodeJS/Express app using handlebars is vulnerable to Local File Read via the layout parameter, potentially leading to Remote Code Execution. The author created a CTF challenge to demonstrate the issue, which was solved by four participants. The fix involves preventing prototype pollution and removing the layout key from render options.Security AffairsUK NCSC's alert urges orgs to fix MobileIron CVE-2020-15505 RCEThe UK NCSC issued an alert urging organizations to patch the critical CVE-2020-15505 remote code execution vulnerability in MobileIron MDM systems. The flaw, discovered in March and patched in June, allows attackers to execute arbitrary code on remote servers. APT groups are actively exploiting it, and the US NSA included it in its top 25 vulnerabilities.AiThorityCyber Risk & Record Web Traffic May Disrupt 2020 Holiday ShoppingImperva released a threat intelligence report on retail cybersecurity, finding web traffic to retail sites spiked 28% over weekly averages after stay-at-home orders. The report details record bot attacks, API vulnerabilities, and DDoS threats, urging retailers to prepare for a surge in holiday shopping traffic.TechSpotChrome zero-day V8 vulnerability found being actively exploitedGoogle patched two actively exploited Chrome zero-days, including a V8 JavaScript engine flaw enabling remote code execution and a sandbox escape on Android. The patches were released on November 3, 2020, and Google recommends immediate updates to both desktop and Android versions.